Cambridge, Massachusetts | August 2021
Clear Scientific recently received continued funding and support to further test and develop our novel atropine injectable therapeutic. Atropine is a previously FDA-approved treatment for acute nerve agent poisoning. Our current formulation demonstrates improved shelf-life stability as well as enhanced treatment benefits against nerve agents. The Phase II extension support enables CSInc to continue testing the efficacy of our improved therapeutic as we progress toward FDA submission of our medicinal formulation.